Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01DK082396 | U.S. NIH Grant/Contract | View source | |
| UL1RR024150 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NIH |
| National Center for Research Resources (NCRR) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study is being undertaken to understand how the Roux-en-Y Gastric Bypass procedure can affect insulin secretion after meals. The hypothesis of this study is the Disposition Index is decreased in subjects who had previously undergone Roux-en-Y Gastric Bypass by glucagon-like peptide-1 (GLP-1) receptor blockade.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Exendin 9, 39 | Experimental | Exendin 9, 39 will be infused at 300pmol/kg/min in either first intervention period or second intervention period. |
|
| Placebo | Placebo Comparator | A saline infusion will be administered in either first intervention period or second intervention period. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Exendin 9, 39 | Drug | Exendin 9,39 is a competitive antagonist of endogenous GLP-1. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Total Disposition Index from Study 1 (Exendin 9,39) to Study 2 (saline) | The total disposition index equals the product of insulin secretion and insulin sensitivity. | Day 1, Day 2 (approximately 2 weeks after day 1) |
Not provided
Not provided
Inclusion Criteria Roux-en-Y Gastric Bypass (RYGB)Subjects:
Inclusion Criteria Healthy Subjects:
Exclusion Criteria all Subjects:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Adrian Vella, M.D. | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | United States |
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C083773 | exendin (9-39) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
A saline infusion will be given to match the study drug infusion. |
|
| D004700 | Endocrine System Diseases |